Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.